Clinical Trial Update: Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating anti-PD-1 alone or with autologous cell therapy in advanced lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: Capital Medical University | Conditions: Lung Cancer, Neoplasms | Phase 1, Phase 2 | Status: COMPLETED